• In May 2026, Hengrui Pharma and Bristol Myers Squibb entered global strategic collaboration and license agreements to advance a portfolio of 13 early-stage oncology, hematology and immunology programs, with potential deal value of up to US$15.20 billion including US$600.00 million upfront and further milestone payments and tiered royalties.
• The cross-border structure, with each company swapping territorial rights and jointly discovering additional assets, signals a deeper two-way integration between Western and Chinese drug development that could meaningfully reshape Bristol Myers Squibb’s early‑pipeline mix and geographic exposure.
• We’ll now examine how this very large Hengrui partnership could alter Bristol Myers Squibb’s risk balance, pipeline diversification, and long‑term investment narrative.

Find 50 companies with promising cash flow potential yet trading below their fair value.

Bristol-Myers Squibb Investment Narrative Recap

To stay a shareholder in Bristol Myers Squibb, you need to believe its newer drugs and partnerships can gradually offset looming patent cliffs on Eliquis and Opdivo, despite consensus forecasts for declining revenue and earnings. The huge Hengrui partnership reshapes the early pipeline but is too immature to change the key near term catalyst, which remains late stage data and execution on current launches, or the main risk of faster erosion in legacy products.

The expanded Tempus AI collaboration ties directly into that near term catalyst by aiming to improve the probability of success in five active clinical programs across oncology and Alzheimer’s. If Tempus’ AI tools sharpen trial design and patient selection, they could modestly influence how effectively BMS turns its broad pipeline and new Hengrui assets into approved, commercial therapies over time.

Yet beneath the recent good news, investors should also weigh the risk that pricing pressure and faster than expected post patent competition could...

Bristol-Myers Squibb's narrative projects $40.8 billion revenue and $9.1 billion earnings by 2029.

Uncover how Bristol-Myers Squibb's forecasts yield a $63.04 fair value, a 11% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts already expected revenue to shrink about 3 percent a year but earnings to climb toward US$10.4 billion, so deals like Hengrui and Tempus may either support that upbeat view or force a rethink, reminding you that opinions on BMS’s risks and potential rewards can differ widely.

Explore 12 other fair value estimates on Bristol-Myers Squibb - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Bristol-Myers Squibb research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Bristol-Myers Squibb research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bristol-Myers Squibb's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.
• Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.